Trivalent influenza virus split vaccine approved for clinical trials
October 14, 2025
Source: drugdu
85
Nancai Intelligence reported on October 13th that Beike BioAnnouncement: Changchun Baike Biotechnology Co., Ltd. received the National Medical Products Administration's announcement on the trivalent influenzaThe clinical trial approval notice for the viral split vaccine (BK-01 adjuvant) was issued. This vaccine is designed to prevent influenza caused by specific influenza virus types, specifically targeting people aged 60 and above, aiming to enhance the immune response in this age group.
https://finance.eastmoney.com/a/202510133532452731.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
